Periodic Reporting for period 1 - NANO-PROTECT (Antimicrobial nano-coatings for hospital textiles to prevent the spread of healthcare associated infections)
Reporting period: 2023-09-01 to 2025-08-31
Summary of the context and overall objectives of the project
Healthcare-associated infections (HCAIs) represent a critical public health challenge in Europe, affecting approximately 3.8 million patients annually in EU/EEA acute care hospitals and causing an estimated 90,000 deaths. Six major HCAIs alone impose healthcare costs of €13-24 billion annually on European health systems. Hospital textiles—including bed linens, surgical gowns, privacy curtains, and patient clothing—serve as significant vectors for pathogen transmission, yet current antimicrobial textile solutions suffer from three fundamental limitations: poor washing durability (typically 10-20 cycles), potential toxicity due to agent leaching, and reliance on energy-intensive manufacturing processes. Compounding this challenge, antimicrobial resistance (AMR) threatens to become one of the leading causes of death globally, with projections estimating 10 million annual deaths by 2050 if current trends continue. Conventional antimicrobial agents used in textiles often accelerate resistance development, creating a vicious cycle that undermines infection control efforts. The NANO-PROTECT project addressed these interconnected challenges by developing next-generation antimicrobial textile coatings that combine effectiveness, durability, safety, and sustainability. The project's overarching objective was to create industrially scalable coating technologies that could significantly reduce HCAI transmission in healthcare settings whilst minimizing antimicrobial resistance development.
Strategic Alignment with EU Priorities: The project directly supports multiple European policy frameworks:
1. European Health Union objectives on HCAI prevention and patient safety
2. EU Action Plan on Antimicrobial Resistance through development of responsible antimicrobial approaches
3. European Green Deal through sustainable manufacturing and circular economy principles
4. European industrial strategy for advanced manufacturing and high-value textile production
Specific Objectives:
1. Develop novel antimicrobial nanoparticles with multiple modes of action (bactericidal, anti-biofilm, anti-virulence) to prevent resistance development
2. Create sustainable coating technologies using bio-based materials and green chemistry principles
3. Demonstrate industrial scalability through pilot-scale manufacturing
4. Ensure safety through comprehensive biocompatibility assessment
5. Validate performance through rigorous antimicrobial testing including washing durability
Expected Impact:
The project pathway to impact encompasses three dimensions:
1. Scientific Impact: Advance the state-of-the-art in antimicrobial materials by demonstrating that multi-mechanism nanoparticle systems can dramatically reduce bacterial resistance development compared to conventional antimicrobial agents, whilst achieving superior washing durability through innovative coating chemistries.
2. Economic and Industrial Impact: Bridge the laboratory-to-industry gap by validating coating technologies at pilot scale, enabling European textile manufacturers to adopt advanced antimicrobial functionalization processes. The projected market for antimicrobial medical textiles within the broader €19.2 billion global medical textile market (2027 projection) represents significant economic opportunities for European industry.
3. Societal Impact: Contribute to improved patient safety and reduced healthcare costs through effective infection prevention. Even modest reductions in HCAI rates could save thousands of lives and hundreds of millions of euros annually across European healthcare systems. The demonstrated minimal resistance development potential addresses the long-term sustainability challenge, ensuring that antimicrobial textiles remain effective tools for infection control rather than contributing to the AMR crisis.
The project's emphasis on bio-based materials (lignin from paper/pulp industry waste, chitosan from crustacean shell waste) and energy-efficient manufacturing processes (room-temperature coating, waterborne formulations) exemplifies sustainable innovation that balances efficacy with environmental responsibility—a critical consideration as healthcare sectors worldwide work to reduce their environmental footprints whilst maintaining high safety standards.
By successfully demonstrating that responsible antimicrobial textiles can be manufactured at industrial scale with exceptional performance characteristics, NANO-PROTECT establishes a foundation for widespread adoption in healthcare facilities throughout Europe and beyond, contributing to resilient healthcare systems capable of maintaining high infection control standards even during periods of increased demand such as pandemic scenarios.
Strategic Alignment with EU Priorities: The project directly supports multiple European policy frameworks:
1. European Health Union objectives on HCAI prevention and patient safety
2. EU Action Plan on Antimicrobial Resistance through development of responsible antimicrobial approaches
3. European Green Deal through sustainable manufacturing and circular economy principles
4. European industrial strategy for advanced manufacturing and high-value textile production
Specific Objectives:
1. Develop novel antimicrobial nanoparticles with multiple modes of action (bactericidal, anti-biofilm, anti-virulence) to prevent resistance development
2. Create sustainable coating technologies using bio-based materials and green chemistry principles
3. Demonstrate industrial scalability through pilot-scale manufacturing
4. Ensure safety through comprehensive biocompatibility assessment
5. Validate performance through rigorous antimicrobial testing including washing durability
Expected Impact:
The project pathway to impact encompasses three dimensions:
1. Scientific Impact: Advance the state-of-the-art in antimicrobial materials by demonstrating that multi-mechanism nanoparticle systems can dramatically reduce bacterial resistance development compared to conventional antimicrobial agents, whilst achieving superior washing durability through innovative coating chemistries.
2. Economic and Industrial Impact: Bridge the laboratory-to-industry gap by validating coating technologies at pilot scale, enabling European textile manufacturers to adopt advanced antimicrobial functionalization processes. The projected market for antimicrobial medical textiles within the broader €19.2 billion global medical textile market (2027 projection) represents significant economic opportunities for European industry.
3. Societal Impact: Contribute to improved patient safety and reduced healthcare costs through effective infection prevention. Even modest reductions in HCAI rates could save thousands of lives and hundreds of millions of euros annually across European healthcare systems. The demonstrated minimal resistance development potential addresses the long-term sustainability challenge, ensuring that antimicrobial textiles remain effective tools for infection control rather than contributing to the AMR crisis.
The project's emphasis on bio-based materials (lignin from paper/pulp industry waste, chitosan from crustacean shell waste) and energy-efficient manufacturing processes (room-temperature coating, waterborne formulations) exemplifies sustainable innovation that balances efficacy with environmental responsibility—a critical consideration as healthcare sectors worldwide work to reduce their environmental footprints whilst maintaining high safety standards.
By successfully demonstrating that responsible antimicrobial textiles can be manufactured at industrial scale with exceptional performance characteristics, NANO-PROTECT establishes a foundation for widespread adoption in healthcare facilities throughout Europe and beyond, contributing to resilient healthcare systems capable of maintaining high infection control standards even during periods of increased demand such as pandemic scenarios.
Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far
Development of Novel Antimicrobial Nanoparticle Platforms:
Three complementary nanoparticle systems were successfully developed to provide comprehensive antimicrobial protection. Silver-chitosan-acylase nanoparticles (AgCS@AC NPs) represent the first integration of quorum-quenching enzymes with antimicrobial nanoparticles for textiles. These hybrid nanoparticles of approximately 40 nm diameter were synthesized through chitosan-mediated silver reduction followed by covalent enzyme attachment. The dual-mode mechanism combines bactericidal activity with anti-virulence properties through bacterial communication disruption. Testing demonstrated complete bacterial growth inhibition at 7 ppm silver concentration with 95% quorum-sensing inhibition and 2.2 log biofilm reduction. Silver-phenolated lignin nanoparticles (AgPLNPs) were developed as bio-based hybrid systems with 8.2 nm core diameter and 192 nm hydrodynamic diameter. These were synthesized via ultrasound-assisted green reduction using lignin, an industrial by-product from paper and pulp manufacturing, as both reducing and stabilizing agent. The phenolic shell provides multiple functional advantages including antioxidant properties, improved colloidal stability, and reduced cytotoxicity compared to bare silver nanoparticles. The system achieved minimum inhibitory concentrations of 0.31 to 0.63 mg/mL demonstrating broad-spectrum activity against key healthcare pathogens. Critically, resistance development studies showed only 2 to 4 fold MIC increases after 30 days of sequential exposure versus 128 to 2048 fold increases for conventional antibiotics, representing a 32 to 512 fold reduction in resistance development potential. PDDA-based polymer dots were synthesized as cationic polymer nanoparticles of 2 to 6 nm diameter via hydrothermal treatment of poly(diallyldimethylammonium chloride) with boric acid. These demonstrated potent antimicrobial activity with MIC values of 0.056 to 0.112 mg/mL through multiple mechanisms including reactive oxygen species generation and membrane disruption via electrostatic interactions. The system showed particularly promising anti-biofilm properties with minimum biofilm eradication concentrations of 0.028 to 0.112 mg/mL for established biofilms, addressing a critical challenge in healthcare infection control.
Innovative Coating Technologies:
Three industrially compatible coating methodologies were developed and optimized for scalability. Digital inkjet printing technology was adapted for enzyme-nanoparticle systems through careful ink formulation optimization to achieve proper rheological properties with viscosity of 7 to 11 mPa·s whilst maintaining enzyme stability. Carboxymethyl cellulose was selected as viscosity modifier due to superior nanoparticle dispersion stability. Piezoelectric printing successfully deposited AgCS@AC NPs onto plasma-treated cotton fabrics with retained enzymatic activity, validated through bioassays showing 95% quorum-sensing inhibition post-printing. The coated fabrics achieved approximately 3 log bacterial reduction, establishing this as the first demonstration of functional enzyme-nanoparticle textile printing. Sono-enzymatic coating represents an innovative single-step process combining ultrasonic nanoparticle deposition with in-situ enzymatic bioadhesive formation. Laccase enzyme catalyzes oxidation of gallic acid and lignin shell phenolics, generating reactive intermediates that undergo coupling reactions to form crosslinked bioadhesive networks with embedded nanoparticles. Acoustic cavitation serves dual purposes of propelling nanoparticles toward fabric surfaces and enhancing enzyme-substrate interactions. The technology was successfully scaled from laboratory samples of 10×10 cm to roll-to-roll processing of 5×0.5 m fabric, representing a 250-fold area increase. Three processing speeds of 0.1 0.2 and 0.6 m/min were evaluated with 0.2 m/min identified as optimal for balancing production efficiency with coating uniformity. The resulting coatings showed enhanced hydrophobicity with contact angle of 116.1 degrees and uniform nanoparticle distribution confirmed by microscopy. Sonochemical coating technology was developed for PDDA-based polymer dots using ultrasonic processing at 20 kHz frequency and 30% amplitude for 30 minutes. The cationic nanoparticles interact electrostatically with negatively charged cellulose whilst hydrogen bonding provides additional anchoring to the fabric surface. This process was successfully scaled to roll-to-roll pilot production operating at 0.1 m/min processing speed, demonstrating uniform coating distribution across industrial-scale fabric lengths.
Performance Validation:
All coated textiles underwent rigorous antimicrobial testing using standardized shake-flask methodology with initial bacterial concentrations of 1.5 to 3.0 × 10⁵ colony forming units per milliliter. AgCS@AC printed fabrics achieved approximately 3 log reduction equivalent to 99.9% killing against Pseudomonas aeruginosa after 3 hour contact. Sono-enzymatically coated AgPLNPs fabrics demonstrated 5.65 to 5.74 log reductions exceeding 99.999% efficacy after 4 hour contact for all three target pathogens including Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. PDDA-PDs coated fabrics achieved similar high efficacy with 5.65 to 6.0 log reductions depending on bacterial strain tested.
The exceptional washing durability represents a major advance over existing antimicrobial textiles. Following standardized hospital laundry protocols at 75°C for 15 minute cycles with non-ionic surfactant, both sono-enzymatic AgPLNPs coatings and sonochemical PDDA-PDs coatings retained greater than 95% antibacterial efficacy after 60 consecutive washing cycles. Specifically, AgPLNPs coatings showed 98.62 to 99.81% bacterial reduction after 60 washes whilst PDDA-PDs coatings maintained 99.51 to 99.998% efficacy depending on bacterial strain. This represents a 3 to 6 fold improvement over typical antimicrobial textile durability of only 10 to 20 cycles. The superior durability stems from covalent crosslinking mechanisms creating stable chemical bonds rather than relying on simple physical deposition of antimicrobial agents.
Silver release kinetics measured via inductively coupled plasma mass spectrometry showed initial burst release of approximately 10% in the first hour attributed to loosely attached surface particles, followed by sustained low-level release with approximately 45% silver retained after 7 days in buffer solution. Critically, release rates remained below detection limits of 6.34 parts per billion during functional antibacterial testing, indicating the primary antimicrobial mechanism is contact-based rather than leaching-dependent. This minimizes environmental accumulation concerns whilst maintaining effective antimicrobial activity.
Safety and Biocompatibility:
Comprehensive cytotoxicity assessment using human dermal fibroblasts and keratinocytes demonstrated excellent biocompatibility of all developed coating systems. After 72 hour indirect exposure using Transwell insert systems that prevent mechanical damage, cell viability measured by AlamarBlue metabolic activity assay remained greater than 85% for all coated fabrics, well exceeding the 70% safety threshold defined by international standards. Live/Dead fluorescence microscopy confirmed predominantly viable cell populations with green fluorescence, showing cell density and morphology comparable to pristine fabric controls. The enhanced biocompatibility compared to conventional silver textiles is attributed to three factors: encapsulation of silver within biopolymer matrices reducing direct silver exposure to cells, minimal leaching due to stable coating attachment via crosslinking, and antioxidant properties of phenolic components in the lignin shell that mitigate oxidative stress.
Key Achievements:
The project successfully delivered three novel antimicrobial nanoparticle platforms demonstrating 32 to 512 fold reduction in bacterial resistance development compared to conventional antibiotics. Three scalable coating technologies were validated at pilot scale with production capacity of 2.5 square meters. All coated fabrics achieved greater than 99% bacterial reduction whilst retaining greater than 95% efficacy after 60 industrial washing cycles. Excellent biocompatibility with greater than 85% cell viability and minimal environmental release was confirmed. The technology readiness level advanced from TRL 3 to 4 at project start to TRL 6 upon completion, positioning the innovations for industrial adoption. Sustainable manufacturing was demonstrated through bio-based materials including lignin and chitosan combined with room-temperature processing methods that eliminate energy-intensive thermal curing.
Three complementary nanoparticle systems were successfully developed to provide comprehensive antimicrobial protection. Silver-chitosan-acylase nanoparticles (AgCS@AC NPs) represent the first integration of quorum-quenching enzymes with antimicrobial nanoparticles for textiles. These hybrid nanoparticles of approximately 40 nm diameter were synthesized through chitosan-mediated silver reduction followed by covalent enzyme attachment. The dual-mode mechanism combines bactericidal activity with anti-virulence properties through bacterial communication disruption. Testing demonstrated complete bacterial growth inhibition at 7 ppm silver concentration with 95% quorum-sensing inhibition and 2.2 log biofilm reduction. Silver-phenolated lignin nanoparticles (AgPLNPs) were developed as bio-based hybrid systems with 8.2 nm core diameter and 192 nm hydrodynamic diameter. These were synthesized via ultrasound-assisted green reduction using lignin, an industrial by-product from paper and pulp manufacturing, as both reducing and stabilizing agent. The phenolic shell provides multiple functional advantages including antioxidant properties, improved colloidal stability, and reduced cytotoxicity compared to bare silver nanoparticles. The system achieved minimum inhibitory concentrations of 0.31 to 0.63 mg/mL demonstrating broad-spectrum activity against key healthcare pathogens. Critically, resistance development studies showed only 2 to 4 fold MIC increases after 30 days of sequential exposure versus 128 to 2048 fold increases for conventional antibiotics, representing a 32 to 512 fold reduction in resistance development potential. PDDA-based polymer dots were synthesized as cationic polymer nanoparticles of 2 to 6 nm diameter via hydrothermal treatment of poly(diallyldimethylammonium chloride) with boric acid. These demonstrated potent antimicrobial activity with MIC values of 0.056 to 0.112 mg/mL through multiple mechanisms including reactive oxygen species generation and membrane disruption via electrostatic interactions. The system showed particularly promising anti-biofilm properties with minimum biofilm eradication concentrations of 0.028 to 0.112 mg/mL for established biofilms, addressing a critical challenge in healthcare infection control.
Innovative Coating Technologies:
Three industrially compatible coating methodologies were developed and optimized for scalability. Digital inkjet printing technology was adapted for enzyme-nanoparticle systems through careful ink formulation optimization to achieve proper rheological properties with viscosity of 7 to 11 mPa·s whilst maintaining enzyme stability. Carboxymethyl cellulose was selected as viscosity modifier due to superior nanoparticle dispersion stability. Piezoelectric printing successfully deposited AgCS@AC NPs onto plasma-treated cotton fabrics with retained enzymatic activity, validated through bioassays showing 95% quorum-sensing inhibition post-printing. The coated fabrics achieved approximately 3 log bacterial reduction, establishing this as the first demonstration of functional enzyme-nanoparticle textile printing. Sono-enzymatic coating represents an innovative single-step process combining ultrasonic nanoparticle deposition with in-situ enzymatic bioadhesive formation. Laccase enzyme catalyzes oxidation of gallic acid and lignin shell phenolics, generating reactive intermediates that undergo coupling reactions to form crosslinked bioadhesive networks with embedded nanoparticles. Acoustic cavitation serves dual purposes of propelling nanoparticles toward fabric surfaces and enhancing enzyme-substrate interactions. The technology was successfully scaled from laboratory samples of 10×10 cm to roll-to-roll processing of 5×0.5 m fabric, representing a 250-fold area increase. Three processing speeds of 0.1 0.2 and 0.6 m/min were evaluated with 0.2 m/min identified as optimal for balancing production efficiency with coating uniformity. The resulting coatings showed enhanced hydrophobicity with contact angle of 116.1 degrees and uniform nanoparticle distribution confirmed by microscopy. Sonochemical coating technology was developed for PDDA-based polymer dots using ultrasonic processing at 20 kHz frequency and 30% amplitude for 30 minutes. The cationic nanoparticles interact electrostatically with negatively charged cellulose whilst hydrogen bonding provides additional anchoring to the fabric surface. This process was successfully scaled to roll-to-roll pilot production operating at 0.1 m/min processing speed, demonstrating uniform coating distribution across industrial-scale fabric lengths.
Performance Validation:
All coated textiles underwent rigorous antimicrobial testing using standardized shake-flask methodology with initial bacterial concentrations of 1.5 to 3.0 × 10⁵ colony forming units per milliliter. AgCS@AC printed fabrics achieved approximately 3 log reduction equivalent to 99.9% killing against Pseudomonas aeruginosa after 3 hour contact. Sono-enzymatically coated AgPLNPs fabrics demonstrated 5.65 to 5.74 log reductions exceeding 99.999% efficacy after 4 hour contact for all three target pathogens including Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. PDDA-PDs coated fabrics achieved similar high efficacy with 5.65 to 6.0 log reductions depending on bacterial strain tested.
The exceptional washing durability represents a major advance over existing antimicrobial textiles. Following standardized hospital laundry protocols at 75°C for 15 minute cycles with non-ionic surfactant, both sono-enzymatic AgPLNPs coatings and sonochemical PDDA-PDs coatings retained greater than 95% antibacterial efficacy after 60 consecutive washing cycles. Specifically, AgPLNPs coatings showed 98.62 to 99.81% bacterial reduction after 60 washes whilst PDDA-PDs coatings maintained 99.51 to 99.998% efficacy depending on bacterial strain. This represents a 3 to 6 fold improvement over typical antimicrobial textile durability of only 10 to 20 cycles. The superior durability stems from covalent crosslinking mechanisms creating stable chemical bonds rather than relying on simple physical deposition of antimicrobial agents.
Silver release kinetics measured via inductively coupled plasma mass spectrometry showed initial burst release of approximately 10% in the first hour attributed to loosely attached surface particles, followed by sustained low-level release with approximately 45% silver retained after 7 days in buffer solution. Critically, release rates remained below detection limits of 6.34 parts per billion during functional antibacterial testing, indicating the primary antimicrobial mechanism is contact-based rather than leaching-dependent. This minimizes environmental accumulation concerns whilst maintaining effective antimicrobial activity.
Safety and Biocompatibility:
Comprehensive cytotoxicity assessment using human dermal fibroblasts and keratinocytes demonstrated excellent biocompatibility of all developed coating systems. After 72 hour indirect exposure using Transwell insert systems that prevent mechanical damage, cell viability measured by AlamarBlue metabolic activity assay remained greater than 85% for all coated fabrics, well exceeding the 70% safety threshold defined by international standards. Live/Dead fluorescence microscopy confirmed predominantly viable cell populations with green fluorescence, showing cell density and morphology comparable to pristine fabric controls. The enhanced biocompatibility compared to conventional silver textiles is attributed to three factors: encapsulation of silver within biopolymer matrices reducing direct silver exposure to cells, minimal leaching due to stable coating attachment via crosslinking, and antioxidant properties of phenolic components in the lignin shell that mitigate oxidative stress.
Key Achievements:
The project successfully delivered three novel antimicrobial nanoparticle platforms demonstrating 32 to 512 fold reduction in bacterial resistance development compared to conventional antibiotics. Three scalable coating technologies were validated at pilot scale with production capacity of 2.5 square meters. All coated fabrics achieved greater than 99% bacterial reduction whilst retaining greater than 95% efficacy after 60 industrial washing cycles. Excellent biocompatibility with greater than 85% cell viability and minimal environmental release was confirmed. The technology readiness level advanced from TRL 3 to 4 at project start to TRL 6 upon completion, positioning the innovations for industrial adoption. Sustainable manufacturing was demonstrated through bio-based materials including lignin and chitosan combined with room-temperature processing methods that eliminate energy-intensive thermal curing.
Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)
The NANO-PROTECT project has delivered three major scientific advances that significantly surpass current antimicrobial textile technologies. Our nanoparticle systems demonstrate only 2-8 fold MIC increases after 30 days of sequential bacterial exposure, compared to 128-2048 fold increases for conventional antibiotics, representing a 32-512 fold reduction in resistance development potential. This breakthrough offers a sustainable solution for infection prevention without contributing to the global antimicrobial resistance crisis. Additionally, our coatings retained >95% antibacterial efficacy after 60 industrial washing cycles, representing a 3-6 fold improvement over typical antimicrobial textiles which lose efficacy after 10-20 washes. Successful scale-up from laboratory to roll-to-roll pilot processing (250-fold area increase) demonstrates industrial feasibility using waterborne processing, room-temperature conditions, and bio-based materials.
Our approach integrates bactericidal activity, anti-biofilm properties, and quorum-quenching capabilities, representing the first successful integration of quorum-quenching enzymes with antimicrobial nanoparticles for textile applications. The systems demonstrate >85% mammalian cell viability, contact-based mechanisms with minimal silver release (<6.34 ppb), and enhanced biocompatibility through biopolymer encapsulation. The advancement from TRL 3-4 to TRL 6 significantly de-risks industrial adoption, providing validated manufacturing parameters, confirmed raw material availability, and commercial viability data.
Healthcare-associated infections affect 3.8 million patients annually in EU/EEA countries, causing 90,000 deaths and costing €13-24 billion annually. The developed technologies offer potential to reduce pathogen transmission, mitigate antimicrobial resistance, improve patient safety, and support pandemic preparedness. Economically, they address the medical textile market projected to reach €19.2 billion by 2027, generate healthcare cost savings, enhance European industrial competitiveness, and create skilled jobs in advanced manufacturing.
Successful market uptake requires coordinated efforts across multiple domains. Further R&D priorities include long-term durability validation, mechanistic studies of resistance prevention, formulation optimization, and broader pathogen validation (€300,000-500,000, 18-24 months). Demonstration activities should include full-scale industrial trials, clinical environment field trials, and application diversification (€1-2 million, 2-3 years). Commercialization pathways include technology licensing, joint development agreements, or spin-off company formation, targeting high-value segments initially with phased market expansion (€2-5 million, 2-5 years).
IP strategy should include patent applications on optimized formulations and novel processes within 6-12 months (€50,000-100,000). Regulatory compliance for Class I medical devices under EU MDR requires biocompatibility testing, quality management certification (ISO 13485), and CE marking (€200,000-400,000, 18-24 months). Standardization contributions should address washing durability protocols, resistance monitoring, and biocompatibility requirements for medical textiles. International collaboration priorities include European textile manufacturing clusters, hospital networks, and selective expansion to US markets with appropriate IP protection. Access to finance includes immediate EIC Accelerator application (€2.5 million) and growth phase venture capital (€5-10 million).
Supportive policy mechanisms include healthcare procurement innovation, regulatory fast-track pathways for AMR-addressing technologies, harmonized European standards, and continued Horizon Europe funding. The NANO-PROTECT outcomes align with EU priorities including the Action Plan on Antimicrobial Resistance, European Green Deal circular economy principles, European Health Union HCAI prevention objectives, and European Industrial Strategy advanced manufacturing competitiveness.
The project has delivered scientifically validated, industrially scalable, and environmentally sustainable antimicrobial textile technologies with demonstrated exceptional performance. Successful market uptake requires estimated investment of €4-8 million over 3-5 years across R&D optimization, clinical demonstration, IP protection, regulatory approval, and market entry. The compelling value proposition addressing the €13-24 billion annual HCAI burden positions these technologies for significant healthcare, economic, and environmental impact, with potential to transition from research excellence to clinical reality benefiting European patients, healthcare systems, and industrial competitiveness.
Our approach integrates bactericidal activity, anti-biofilm properties, and quorum-quenching capabilities, representing the first successful integration of quorum-quenching enzymes with antimicrobial nanoparticles for textile applications. The systems demonstrate >85% mammalian cell viability, contact-based mechanisms with minimal silver release (<6.34 ppb), and enhanced biocompatibility through biopolymer encapsulation. The advancement from TRL 3-4 to TRL 6 significantly de-risks industrial adoption, providing validated manufacturing parameters, confirmed raw material availability, and commercial viability data.
Healthcare-associated infections affect 3.8 million patients annually in EU/EEA countries, causing 90,000 deaths and costing €13-24 billion annually. The developed technologies offer potential to reduce pathogen transmission, mitigate antimicrobial resistance, improve patient safety, and support pandemic preparedness. Economically, they address the medical textile market projected to reach €19.2 billion by 2027, generate healthcare cost savings, enhance European industrial competitiveness, and create skilled jobs in advanced manufacturing.
Successful market uptake requires coordinated efforts across multiple domains. Further R&D priorities include long-term durability validation, mechanistic studies of resistance prevention, formulation optimization, and broader pathogen validation (€300,000-500,000, 18-24 months). Demonstration activities should include full-scale industrial trials, clinical environment field trials, and application diversification (€1-2 million, 2-3 years). Commercialization pathways include technology licensing, joint development agreements, or spin-off company formation, targeting high-value segments initially with phased market expansion (€2-5 million, 2-5 years).
IP strategy should include patent applications on optimized formulations and novel processes within 6-12 months (€50,000-100,000). Regulatory compliance for Class I medical devices under EU MDR requires biocompatibility testing, quality management certification (ISO 13485), and CE marking (€200,000-400,000, 18-24 months). Standardization contributions should address washing durability protocols, resistance monitoring, and biocompatibility requirements for medical textiles. International collaboration priorities include European textile manufacturing clusters, hospital networks, and selective expansion to US markets with appropriate IP protection. Access to finance includes immediate EIC Accelerator application (€2.5 million) and growth phase venture capital (€5-10 million).
Supportive policy mechanisms include healthcare procurement innovation, regulatory fast-track pathways for AMR-addressing technologies, harmonized European standards, and continued Horizon Europe funding. The NANO-PROTECT outcomes align with EU priorities including the Action Plan on Antimicrobial Resistance, European Green Deal circular economy principles, European Health Union HCAI prevention objectives, and European Industrial Strategy advanced manufacturing competitiveness.
The project has delivered scientifically validated, industrially scalable, and environmentally sustainable antimicrobial textile technologies with demonstrated exceptional performance. Successful market uptake requires estimated investment of €4-8 million over 3-5 years across R&D optimization, clinical demonstration, IP protection, regulatory approval, and market entry. The compelling value proposition addressing the €13-24 billion annual HCAI burden positions these technologies for significant healthcare, economic, and environmental impact, with potential to transition from research excellence to clinical reality benefiting European patients, healthcare systems, and industrial competitiveness.